A 24-Week, Flexible-Dose, Open-Label Extension Study of Lurasidone for the Treatment of Bipolar I Depression.

Trial Profile

A 24-Week, Flexible-Dose, Open-Label Extension Study of Lurasidone for the Treatment of Bipolar I Depression.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Lurasidone (Primary)
  • Indications Bipolar I disorders
  • Focus Adverse reactions; Registrational
  • Acronyms PREVAIL-Extension
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 24 May 2017 Results of post hoc analysis presented at the 170th Annual Meeting of the American Psychiatric Association
    • 23 May 2016 Results published in the journal Depression and Anxiety, as per Sunovion media release.
    • 01 Sep 2015 Results presented at the 28th Annual Congress of the European College of Neuropsychopharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top